Cancer drug combo cut progression or death risk 43% versus standard care, FDA grants priority review
Priority review could shorten the path to market for the combination regimen.
Read at Stock Titan →Full coverage · 7 outlets
- Stock Titan · lead
- MSNGenmab, AbbVie drug combo cuts progression risk 51% in lymphoma trial
- ReutersIncyte blood cancer drug combo reduces disease-progression risk but with high side-effect rate
- YahooGenmab jumps as its lymphoma drug combo with AbbVie cuts progression, death risk
- AjmcTopline Data Show Zanubrutinib Plus Rituximab Cut Risk of Progression or Death 43% Over BR in Frontline Treatment of MCL
- MedicalxpressImmunotherapy combo extends survival for patients with aggressive small cell lung cancer, based on trial results
- UsnewsIncyte Blood Cancer Drug Combo Reduces Disease-Progression Risk but With High Side-Effect Rate